Scribe Therapeutics Inc.

Scribe Therapeutics Inc.

NNASDAQ:SCTX
15.37
USD
-0.99
(-6.05%)
-0.40EPS
Mar 03Next Earn

Important Dates

Scribe Therapeutics Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, Scribe Therapeutics Inc. has 17.58M shares outstanding.

Shares Outstanding17.58M

Financial Position

As of June 30, 2026, Scribe Therapeutics Inc. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -26.25, indicating conservative leverage, while an interest coverage ratio of -31.20 demonstrates limited ability to service its debt obligations.

Current Ratio0.57
Quick Ratio0.56
Debt / Equity-26.25
Interest Coverage-31.20

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2026. The company generates approximately 19,571.43 in revenue per employee across its workforce of 98.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee19,571.43
Employee Count98.00

Taxes

USD

Over the twelve months ended June 30, 2026, Scribe Therapeutics Inc. recorded 212,000.00 in income tax expense.

Income Tax212,000.00

Stock Price Statistics

USD

These figures are as of the close on November 16, 2026.

50-Day Moving Average20.86

Income Statement

USD

These figures cover the twelve months ended June 30, 2026.

Pretax Income-6.26M

Balance Sheet

USD

As of June 30, 2026, Scribe Therapeutics Inc. holds 43.01M in cash and equivalents against 43.27M in total debt, resulting in a net debt position of 2.21M. Total book value stands at -164.85M, with working capital of -33.59M providing operational flexibility.

Cash & Cash Equivalents43.01M
Total Debt43.27M
Net Debt2.21M
Equity (Book Value)-164.85M
Book Value Per Share-9.38
Working Capital-33.59M

Cash Flow

USD

These figures cover the twelve months ended June 30, 2026. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -5.35M - equivalent to -0.33 per share.

Capital Expenditures-10,000.00
Free Cash Flow-5.35M
FCF Per Share-0.33

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -489.83 and net profit margin of -337.70 provide insight into operational efficiency.

Operating Margin-489.83
Pretax Margin-326.64
Profit Margin-337.70